NASDAQ:RYTM

Rhythm Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy RYTM

*Your capital is at risk

$109.84

+1.58 (+1.46%)

At Close: Jun 26, 2026

Rhythm Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 2.40. In total, the insiders bought 813.42K and sold 86.51K RYTM shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	2.40
● Buy	813.42K shares
● Sell	86.51K shares
71% Buy Activity Weak Negative Correlation
Buy Signal Low Confidence Jun 24, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 24, 2026 Buy	Stock Option (right to buy) A-Award	Jean Christophe Director	Director	3 691 Value: $397.0K
Jun 24, 2026 Buy	Stock Option (right to buy) A-Award	Mcgirr David W J Director	Director	3 691 Value: $397.0K
Jun 24, 2026 Buy	Restricted Stock Units A-Award	Mcgirr David W J Director	Director	2 324 Value: $249.9K
Jun 24, 2026 Buy	Stock Option (right to buy) A-Award	Good Jennifer L Director	Director	3 691 Value: $397.0K
Jun 24, 2026 Buy	Restricted Stock Units A-Award	Arbuckle Stuart A Director	Director	2 324 Value: $249.9K
Jun 24, 2026 Buy	Stock Option (right to buy) A-Award	Arbuckle Stuart A Director	Director	3 691 Value: $397.0K
Jun 24, 2026 Buy	Restricted Stock Units A-Award	Good Jennifer L Director	Director	2 324 Value: $249.9K
Jun 24, 2026 Buy	Restricted Stock Units A-Award	Tetrault Lynn A. Director	Director	2 324 Value: $249.9K
Jun 24, 2026 Buy	Stock Option (right to buy) A-Award	Tetrault Lynn A. Director	Director	3 691 Value: $397.0K
Jun 24, 2026 Buy	Restricted Stock Units A-Award	Jean Christophe Director	Director	2 324 Value: $249.9K
Jun 23, 2026 Buy	Common Stock M-Exempt	Jean Christophe Director	Director	4 712 Value: $500.4K
Jun 23, 2026 Buy	Restricted Stock Units M-Exempt	Mcgirr David W J Director	Director	4 712 Value: $500.4K
Jun 23, 2026 Buy	Common Stock M-Exempt	Good Jennifer L Director	Director	4 712 Value: $500.4K
Jun 23, 2026 Buy	Restricted Stock Units M-Exempt	Arbuckle Stuart A Director	Director	4 712 Value: $500.4K
Jun 23, 2026 Buy	Common Stock M-Exempt	Arbuckle Stuart A Director	Director	4 712 Value: $500.4K
Jun 23, 2026 Buy	Restricted Stock Units M-Exempt	Tetrault Lynn A. Director	Director	4 712 Value: $500.4K
Jun 23, 2026 Buy	Restricted Stock Units M-Exempt	Good Jennifer L Director	Director	4 712 Value: $500.4K
Jun 23, 2026 Buy	Common Stock M-Exempt	Tetrault Lynn A. Director	Director	4 712 Value: $500.4K
Jun 23, 2026 Buy	Common Stock M-Exempt	Mcgirr David W J Director	Director	4 712 Value: $500.4K
Jun 23, 2026 Buy	Restricted Stock Units M-Exempt	Jean Christophe Director	Director	4 712 Value: $500.4K
Jun 22, 2026 Buy	Stock Option (right to buy) M-Exempt	Tetrault Lynn A. Director	Director	37 000 Value: $1.05M
Jun 22, 2026 Sell	Common Stock S-Sale	Tetrault Lynn A. Director	Director	37 000 Value: $3.71M
Jun 22, 2026 Buy	Common Stock M-Exempt	Tetrault Lynn A. Director	Director	37 000 Value: $1.05M
May 18, 2026 Buy	Stock Options (Right to Buy) M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	3 000 Value: $53.6K
May 18, 2026 Buy	Common Stock M-Exempt	Smith Hunter C Chief Financial Officer	C-Suite Officer	3 000 Value: $53.6K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT RHYTHM PHARMACEUTICALS INC

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström s...

Read Full Profile Here